Compare LSAK & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LSAK | EYPT |
|---|---|---|
| Founded | 1997 | 1987 |
| Country | South Africa | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 411.8M | 419.9M |
| IPO Year | 2005 | 2005 |
| Metric | LSAK | EYPT |
|---|---|---|
| Price | $4.20 | $3.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $31.80 |
| AVG Volume (30 Days) | 90.0K | ★ 4.0M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 102.63 | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $721,554,000.00 | $7,539,000.00 |
| Revenue This Year | $14.35 | N/A |
| Revenue Next Year | $8.60 | $3,115.57 |
| P/E Ratio | $141.33 | ★ N/A |
| Revenue Growth | ★ 9.38 | N/A |
| 52 Week Low | $3.62 | $3.42 |
| 52 Week High | $5.54 | $19.11 |
| Indicator | LSAK | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 35.81 | 31.98 |
| Support Level | N/A | $3.95 |
| Resistance Level | $4.99 | $14.72 |
| Average True Range (ATR) | 0.18 | 0.32 |
| MACD | -0.02 | 0.22 |
| Stochastic Oscillator | 15.00 | 39.33 |
Lesaka Technologies Inc provides payment solutions, transaction processing solutions, and financial technologies. The company operates three reportable segments: Merchant, Consumer and Enterprise. Merchant, which focuses on both formal and informal sector merchants. Consumer, which focuses on individuals who have historically been excluded from traditional financial services and to whom it offers transactional accounts (banking), insurance, lending (short-term loans), payments solutions and various value-added services; and Enterprise, which comprises large-scale corporate and government organizations, including but not limited to banks, mobile network operators (MNOs) and municipalities, and, through Recharger, landlords utilizing Recharger's prepaid electricity metering solution.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.